Literature DB >> 19752372

Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction.

Jennifer A Dixon1, Robert C Gorman, Robert E Stroud, Shenikqua Bouges, Hamamoto Hirotsugu, Joseph H Gorman, Timothy P Martens, Silviu Itescu, Michael D Schuster, Theodore Plappert, Martin G St John-Sutton, Francis G Spinale.   

Abstract

BACKGROUND: Targeted delivery of mesenchymal precursor cells (MPCs) can modify left ventricular (LV) cellular and extracellular remodeling after myocardial infarction (MI). However, whether and to what degree LV remodeling may be affected by MPC injection post-MI, and whether these effects are concentration-dependent, remain unknown. METHODS AND
RESULTS: Allogeneic MPCs were expanded from sheep bone marrow, and direct intramyocardial injection was performed within the borderzone region 1 hour after MI induction (coronary ligation) in sheep at the following concentrations: 25x10(6) (25 M, n=7), 75x10(6) (75 M, n=7), 225x10(6) (225 M, n=10), 450x10(6) (450 M, n=8), and MPC free media only (MI Only, n=14). LV end diastolic volume increased in all groups but was attenuated in the 25 and 75 M groups. Collagen content within the borderzone region was increased in the MI Only, 225, and 450 M groups, whereas plasma ICTP, an index of collagen degradation, was highest in the 25 M group. Within the borderzone region matrix metalloproteinases (MMPs) and MMP tissue inhibitors (TIMPs) also changed in a MPC concentration-dependent manner. For example, borderzone levels of MMP-9 were highest in the 25 M group when compared to the MI Only and other MPC treatment group values.
CONCLUSIONS: MPC injection altered collagen dynamics, MMP, and TIMP levels in a concentration-dependent manner, and thereby influenced indices of post-MI LV remodeling. However, the greatest effects with respect to post-MI remodeling were identified at lower MPC concentrations, thus suggesting a therapeutic threshold exists for this particular cell therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19752372      PMCID: PMC2752314          DOI: 10.1161/CIRCULATIONAHA.108.842302

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

1.  Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction.

Authors:  Raj R Makkar; Matthew J Price; Michael Lill; Malka Frantzen; Kaname Takizawa; Thomas Kleisli; Jie Zheng; Saibal Kar; Robert McClelan; Takeshi Miyamota; Justin Bick-Forrester; Michael C Fishbein; Prediman K Shah; James S Forrester; Behrooz Sharifi; Peng-Sheng Chen; Mohammed Qayyum
Journal:  J Cardiovasc Pharmacol Ther       Date:  2005-12       Impact factor: 2.457

Review 2.  Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.

Authors:  Davy Vanhoutte; Mark Schellings; Yigal Pinto; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2005-12-19       Impact factor: 10.787

3.  Amelogenin cross-amplification in the family Bovidae and its application for sex determination.

Authors:  Rosemarie Weikard; Christian Pitra; Christa Kühn
Journal:  Mol Reprod Dev       Date:  2006-10       Impact factor: 2.609

4.  Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.

Authors:  Gerd P Meyer; Kai C Wollert; Joachim Lotz; Jan Steffens; Peter Lippolt; Stephanie Fichtner; Hartmut Hecker; Arnd Schaefer; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler
Journal:  Circulation       Date:  2006-03-06       Impact factor: 29.690

Review 5.  The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease.

Authors:  Begoña López; Arantxa González; Ramón Querejeta; Javier Díez
Journal:  J Hypertens       Date:  2005-08       Impact factor: 4.844

6.  Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts.

Authors:  Joshua D Lovelock; Andrew H Baker; Feng Gao; Jing-Fei Dong; Angela L Bergeron; Willie McPheat; Natarajan Sivasubramanian; Douglas L Mann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-02       Impact factor: 4.733

7.  Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial.

Authors:  Marc Hendrikx; Karen Hensen; Christel Clijsters; Hanne Jongen; Remco Koninckx; Eric Bijnens; Michel Ingels; Axel Jacobs; Robert Geukens; Paul Dendale; Johan Vijgen; Dagmara Dilling; Paul Steels; Urbain Mees; Jean-Luc Rummens
Journal:  Circulation       Date:  2006-07-04       Impact factor: 29.690

8.  Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium.

Authors:  Timothy P Martens; Fiona See; Michael D Schuster; Hugo P Sondermeijer; Marco M Hefti; Andrew Zannettino; Stan Gronthos; Tetsunori Seki; Silviu Itescu
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-03

9.  Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction.

Authors:  Ketil Lunde; Svein Solheim; Svend Aakhus; Harald Arnesen; Michael Abdelnoor; Torstein Egeland; Knut Endresen; Arnfinn Ilebekk; Arild Mangschau; Jan G Fjeld; Hans Jørgen Smith; Eli Taraldsrud; Haakon Kiil Grøgaard; Reidar Bjørnerheim; Magne Brekke; Carl Müller; Einar Hopp; Asgrimur Ragnarsson; Jan E Brinchmann; Kolbjørn Forfang
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

10.  Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling.

Authors:  Lepeng Zeng; Qingsong Hu; Xiaohong Wang; Abdul Mansoor; Joseph Lee; Julia Feygin; Ge Zhang; Piradeep Suntharalingam; Sherry Boozer; Abner Mhashilkar; Carmelo J Panetta; Cory Swingen; Robert Deans; Arthur H L From; Robert J Bache; Catherine M Verfaillie; Jianyi Zhang
Journal:  Circulation       Date:  2007-03-26       Impact factor: 29.690

View more
  42 in total

1.  Cell therapy for refractory angina: time for more ACTion.

Authors:  Peter J Psaltis; Robert D Simari
Journal:  Stem Cell Res Ther       Date:  2011-11-09       Impact factor: 6.832

Review 2.  Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.

Authors:  James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

3.  Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices.

Authors:  Deborah D Ascheim; Annetine C Gelijns; Daniel Goldstein; Lemuel A Moye; Nicholas Smedira; Sangjin Lee; Charles T Klodell; Anita Szady; Michael K Parides; Neal O Jeffries; Donna Skerrett; Doris A Taylor; J Eduardo Rame; Carmelo Milano; Joseph G Rogers; Janine Lynch; Todd Dewey; Eric Eichhorn; Benjamin Sun; David Feldman; Robert Simari; Patrick T O'Gara; Wendy C Taddei-Peters; Marissa A Miller; Yoshifumi Naka; Emilia Bagiella; Eric A Rose; Y Joseph Woo
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 4.  Towards the generation of patient-specific patches for cardiac repair.

Authors:  Giancarlo Forte; Stefania Pagliari; Francesca Pagliari; Mitsuhiro Ebara; Paolo Di Nardo; Takao Aoyagi
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

5.  A dosing study of bone marrow mononuclear cells for transendocardial injection in a pig model of chronic ischemic heart disease.

Authors:  Guilherme V Silva; Marlos R Fernandes; Cristiano O Cardoso; Ricardo R Sanz; Edie M Oliveira; Pilar Jimenez-Quevedo; Javier Lopez; Franca S Angeli; Yi Zheng; James T Willerson; Emerson C Perin
Journal:  Tex Heart Inst J       Date:  2011

6.  Intramyocardial, autologous CD34+ cell therapy for refractory angina.

Authors:  Douglas W Losordo; Timothy D Henry; Charles Davidson; Joon Sup Lee; Marco A Costa; Theodore Bass; Farrell Mendelsohn; F David Fortuin; Carl J Pepine; Jay H Traverse; David Amrani; Bruce M Ewenstein; Norbert Riedel; Kenneth Story; Kerry Barker; Thomas J Povsic; Robert A Harrington; Richard A Schatz
Journal:  Circ Res       Date:  2011-07-07       Impact factor: 17.367

Review 7.  An update on stem cell therapies for acute coronary syndrome.

Authors:  Peter J Psaltis; Daniel B Spoon; Dennis T L Wong; Rajiv Gulati
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

Review 8.  Stem cell mechanisms during left ventricular remodeling post-myocardial infarction: Repair and regeneration.

Authors:  Rogelio Zamilpa; Mary M Navarro; Iris Flores; Sy Griffey
Journal:  World J Cardiol       Date:  2014-07-26

Review 9.  Pathophysiology of myocardial injury and remodeling: implications for molecular imaging.

Authors:  Jennifer A Dixon; Francis G Spinale
Journal:  J Nucl Med       Date:  2010-04-15       Impact factor: 10.057

Review 10.  Cardiac regeneration using pluripotent stem cells--progression to large animal models.

Authors:  James J H Chong; Charles E Murry
Journal:  Stem Cell Res       Date:  2014-07-06       Impact factor: 2.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.